GPR119 agonists are potential novel oral agents for the treatment of diabesity

被引：0
|
作者：
Fyfe, Matthew
White, Jonathan
Widdowson, Peter
Overton, Hilary
Reynet, Christine
机构：
来源：
DIABETES | 2007年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A142 / A142
页数：1
相关论文
共 50 条
  • [1] GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity
    Fyfe, Matthew C. T.
    McCormack, James G.
    Overton, Hilary A.
    Procter, Martin J.
    Reynet, Christine
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (04) : 403 - 413
  • [2] Discovery of novel, orally active, synthetic GPR119 agonists as potential agents for treatment of obesity and associated metabolic disorders
    Fyfe, Matthew
    Overton, Hilary
    White, Jonathan
    Jones, Robert
    Sorensen, Rikke Veggerby
    Reynet, Christine
    [J]. DIABETES, 2006, 55 : A81 - A81
  • [3] GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus
    Manaithiya, Ajay
    Alam, Ozair
    Sharma, Vrinda
    Naim, Mohd. Javed
    Mittal, Shruti
    Khan, Imran A.
    [J]. BIOORGANIC CHEMISTRY, 2021, 113
  • [4] The Emergence of GPR119 Agonists as Anti-Diabetic Agents
    Jones, Robert M.
    Leonard, James N.
    [J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 44, 2009, 44 : 149 - 170
  • [5] Anti-Diabetic Potential of Novel, Small Molecule GPR119 Agonists
    Nagarathnam, Dhanapalan
    Varanasi, Kanthikiran
    Routhu, Kasiviswanath
    Muthuppalaniappan, Meyyappan
    Merikapudi, Gayatriswaroop
    Veeraraghavan, Sridhar
    Prasanna, R.
    Viswanadha, Srikant
    Vakkalanka, Swaroop
    [J]. DIABETES, 2012, 61 : A76 - A76
  • [6] GPR119 agonists for the treatment of type 2 diabetes
    Jones, Robert M.
    Leonard, James N.
    Buzard, Daniel J.
    Lehmann, Juerg
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (10) : 1339 - 1359
  • [7] GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119
    Kang, Sang-Uk
    [J]. DRUG DISCOVERY TODAY, 2013, 18 (23-24) : 1309 - 1315
  • [8] The therapeutic potential of GPR119 agonists for type 2 diabetes
    Ohishi, Takahide
    Yoshida, Shigeru
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (03) : 321 - 328
  • [9] Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists
    Azimioara, Mihai
    Alper, Phil
    Cow, Christopher
    Mutnick, Daniel
    Nikulin, Victor
    Lelais, Gerald
    Mecom, John
    McNeill, Matthew
    Michellys, Pierre-Yves
    Wang, Zhiliang
    Reding, Esther
    Paliotti, Michael
    Li, Jing
    Bao, Dingjiu
    Zoll, Jocelyn
    Kim, Young
    Zimmerman, Matthew
    Groessl, Todd
    Tuntland, Tove
    Joseph, Sean B.
    McNamara, Peter
    Seidel, H. Martin
    Epple, Robert
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (23) : 5478 - 5483
  • [10] GPR119 Expression in Islets and the Effects of GPR119 Agonists on Insulin Secretion In Vitro and In Vivo
    Moran, B. M.
    Abdel-Wahab, Y. H. A.
    Flatt, P. R.
    McKillop, A. M.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2013, 182 : S404 - S404
12345